-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Benzinga·08/27/2026 13:44:04
Listen to the news
Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.